Over 170 carefully curated, well-characterized patient-derived xenograft tumor models are available for use in your facility, or use Horizon’s comprehensive preclinical in vivo efficacy service.
Cancer biology is complex. Fortunately, oncology researchers have more tools than ever before to aid in the understanding of a particular type of cancer, and to translate this research into the clinic. Tumor heterogeneity is a major challenge in oncology research and drug development. Examination of cancer cell lines does not offer a comprehensive view of a tumor, and it can be informative to examine patient-derived xenograft models of tumors. Patient derived xenograft models can make a significant difference in the way we understand biology and medicine by more closely recapitulating the heterogeneity found in cancers.
Patient Derived Xenograft models are typically implanted as dissociated cells or tumor fragments into immunodeficient mouse models which may then be used for in vivo efficacy studies, allowing you to accelerate your oncology research or drug discovery and development programs, including applications for:
Horizon offers our collections as ungrafted PDX suspensions or as comprehensive in vivo efficacy studies. For services, simply provide us with your test articles, and our team of expert scientists will demonstrate their effect on PDX grown in immunodeficient mice. Horizon’s offerings and capabilities include:
See our catalog of patient derived xenograph animal models:
Horizon Discovery has strategically partnered with exceptional institutions to provide access to the best, most characterized Patient Derived Xenograft models for breast cancers and melanomas.
With Washington University School of Medicine in St. Louis, Missouri, we exclusively offer the highly characterized WHIM (Washington University Human-in-Mouse) breast cancer PDX collection.
More recently, we have partnered with The Wistar Institute of Anatomy and Biology in Philadelphia, Pennsylvania, to exclusively offer a subset of their large collection of highly characterized melanoma PDX models.